Furthermore, we also investigated whether pathology (i.e. the 6-OHDA rat model of PD) prompted changes in oligomer formation, which would correlate with some of the observed PD pathophysiological features, and thus provide a rationale for appropriate D2R-A2AR oligomer-based pharmacotherapy. Here, DRD2 is linked to Parkinson disease.